Evidence map›Paper›PMID 36297421›Full record

ArticlePharmaceutics2022

Characterization of Neutralizing Human Anti-Tetanus Monoclonal Antibodies Produced by Stable Cell Lines.

Tania Maria Manieri, Daniela Yumi Takata, Roselaine Campos Targino, Wagner Quintilio, João Victor Batalha-Carvalho, Camila Maria Lucia da Silva, Ana Maria Moro

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tania Maria ManieriBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.ORCID 0000-0003-1152-7425
Daniela Yumi TakataBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.ORCID 0000-0001-6369-1775
Roselaine Campos TarginoBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.
Wagner QuintilioBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.ORCID 0000-0002-3382-8184
João Victor Batalha-CarvalhoBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.ORCID 0000-0002-1526-6915
Camila Maria Lucia da SilvaBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.
Ana Maria MoroBiopharmaceuticals Laboratory, Butantan Institute, Sao Paulo 05503-900, Brazil.ORCID 0000-0002-0650-7764
Instituto Butantan · BRUniversidade de São Paulo · BR

Funding

National Council for Scientific and Technological Development 2020/07040-1São Paulo Research Foundation 2105/15611-0, 2016-08782-6, 2019/10724-2, 2020/07040-1
6 · The paper itself

Abstract

Tetanus toxin (TeNT) is produced by

Indexed as

affinityFc gamma receptorglycosylationGT1bneutralizationSPRtetanus toxintherapeutic antibodyvector construction

Identifiers

PMID36297421
PMCPMC9611486
OpenAlexW4296743658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.